TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Cowen Announces Dr. Yaron Werber to Join Equity Research Team as a Senior Biotech Analyst

NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) today announced that Dr. Yaron Werber will join the Company’s equity research team as a senior biotechnology analyst, starting on September 24, 2018.  Dr. Werber will be joining Cowen from Ovid Therapeutics Inc. (“Ovid”), a biopharmaceutical company, where he served as Chief Business and Financial Officer.  Dr. Werber joined Ovid in 2015 after spending nearly 15 years as a highly-ranked biotechnology research analyst at Citi Research and Cowen.  Dr. Werber will be based in New York and will report to Robert Fagin, Cowen’s Director of Research. 

“We are thrilled to welcome Yaron back to equity research and back to Cowen, where he began his impressive career in biotech.  As a trained medical doctor, respected public company CFO and a proven sell-side analyst, Yaron is an outstanding addition to Cowen’s leading healthcare and biotech research team, and will be part of a highly collaborative group of industry experts dedicated to helping us deliver on our number one priority for clients: outperformance,” said Jeffrey M. Solomon, Cowen’s Chief Executive Officer. 

Robert Fagin added, “Cowen’s healthcare and biotech research team is renowned for its sophisticated, authoritative and agenda-setting analysis.  Yaron’s deep experience and insights will broaden the value we provide our clients even further.”

Cowen’s research department has 57 senior analysts covering 900 securities across multiple sectors, as well as a deep Washington policy team.

At Ovid, Dr. Werber was Chief Business Officer since July 2016, and Chief Financial Officer since June 2015.  Prior to that, Dr. Werber was a Managing Director at Citi Research, and the Head of the Healthcare and Biotech Equity Research teams. He was highly ranked in the Institutional Investor All-America Research Team poll, and ranked among the top five analysts in the biotech sector in the Wall Street Journal “Best on the Street Survey.”  Previously, Dr. Werber was Senior Biotech Analyst and Vice President at SG Cowen Securities. He began his career in academic research, was director of business development at NotifyMD, a privately held e-health company, and also consulted to leading healthcare organizations. Dr. Werber received a BS degree in Biology from Tufts University and a combined MD/MBA degree from Tufts University School of Medicine.

About Cowen Inc.
Cowen Inc. is a diversified financial services firm and, together with its consolidated subsidiaries, provides investment management, investment banking, research, sales and trading, prime brokerage, global clearing and commission management through its two business segments: Cowen Investment Management and its affiliates make up the Company’s investment management segment, while Cowen and Company, a member of FINRA and SIPC, and its affiliates make up the Company’s investment bank segment. Cowen Investment Management provides investment management solutions to a global client base and manages a significant portion of Cowen’s proprietary capital. Cowen and its affiliates offer industry focused investment banking for growth-oriented companies, domain knowledge-driven research, a sales and trading platform for institutional investors, global clearing and commission management services and also a comprehensive suite of prime brokerage services. Founded in 1918, the firm is headquartered in New York and has offices worldwide. To download Cowen’s investor relations app, which offers access to SEC filings, news releases, webcasts and presentations, please visit the App Store for iPhone and iPad or Google Play for Android mobile devices.

Media Contacts:
Lynda Caravello

Gagnier Communications
Dan Gagnier


Source: Cowen Inc.